NURS FPX 4015 Assessment 5 Comprehensive Head-to-Toe Assessment

Student name

Capella University

NURS-FPX4015 Pathophysiology, Pharmacology, and Physical Assessment: A Holistic Approach to Patient-Centered Care

Professor Name

Submission Date

Comprehensive Head-to-Toe Assessment

Hello, my name is [Student Name]. It is a test that involves a body check-up whose findings are an elaborate and methodical report of the overall health status of a patient. It starts with inspection and palpation and moves on to the evaluation of each of the body systems, and does not miss out on anything. The approach helps to detect the subtle variations in time, encourages a holistic understanding, and enables an early intervention. Ultimately, this is an assessment that concerns competent individualized care planning.

Conducts Accurate Patient Assessment

Explains Diagnosis and Findings

In our physical examination, I observed that you move and speak slowly, and we call this psychomotor retardation. You have also lost about ten pounds in the past several weeks without even making any effort, and you have told me that you are waking up a few times in the night, and you are unable to fall asleep again. Your expression was rather dull when we evaluated it, and you have stated that you feel down on most days and have complained of constant lack of energy and motivation. All these are strong indicators because they are signs of the way people act, their appetites and sleeping problems.

We may compare our results with the diagnostic criteria of MDD by adding what we have observed, your slowness in movements, unwilling weight loss and disturbed sleep to what you have reported, that is, constant sadness, lack of interest in activities and exhaustion. In other words, we are attempting to identify a mix of symptoms, which last at least two weeks, and significantly impair a person to live normally (Bains & Abdijadid, 2025). We also exclude other health conditions that can otherwise manifest as depression through the use of your regular thyroid and vitamin D. This is a good step since it will ensure that we are certain that your symptoms are not caused by some other possible underlying physical complications, and it is something that will help us direct our treatment effort towards the depression.

When I present these findings to you, I would want you to realize that you are suffering from a well-known medical condition, and it is not your fault. I describe why the depressed person has slowed movements and sleeping problems because the brain chemicals, such as serotonin and norepinephrine, that keep people in a good mood and energetic are unbalanced (Cui et al., 2024).

Your weight varies in relation to not only the changes in your appetite but also how your body copes with energy when it responds to stress. Interpretation all observations in the context of the changes in the body chemistry and brain functioning, not your weakness, provides you with the right context, which makes you feel empowered to contribute to your treatment plan, as well as being precisely sure what we are working on together.

Discusses Pharmacological Treatment Options

The most widespread first-line pharmacotherapy of MDD is based on SSRIs, in particular, citalopram, sertraline, and fluoxetine, and SNRIs, i.e., venlafaxine or duloxetine. Bupropion or mirtazapine can be used in older adults with fatigue or sleep disturbance as the primary problem. All these agents have their effects by increasing monoamine neurotransmission; hence, they are effective in stabilizing mood and regulating energy levels in the long run (weeks) (Kukucka et al., 2024). Monotherapy is not deemed adequate, so it can be complemented with a low dose of atypical antipsychotics, lithium, or regulation. The best current practices in treatment selection should be the initiation of low-dose treatment in elderly patients and monitoring efficacy and tolerability during acute treatment, continuation and maintenance.

The pharmacologic plan is based on the information about Ivy and her comorbid hypertension that is controlled by lisinopril and hydrochlorothiazide, her age and the history of discontinuation syndrome with venlafaxine. Cardiovascular interactions of SSRIs are not many, but they might lead to hyponatremia, in particular, in combination with diuretics; her sodium level must be monitored regularly.

Escitalopram also interacts with the cytochrome P450, which is taken into account when considering its safety in the context of her current regimen, unlike SNRIs, which can increase blood pressure and, therefore, their use should be avoided (Chu & Wadhwa, 2025). Her effective toleration of melatonin as a hypnotic agent implies complementary non-pharmacologic interventions, but a new agent should be cross-referenced to prevent drug-drug interactions and modified to renal and hepatic conditions.

Ivy needs to be given the right directions regarding the time frames and side effects that she should anticipate when taking or adjusting antidepressants. The most frequent side effects in the early stages include nausea, vomiting, diarrhea, headache, insomnia or somnolence, and sexual dysfunction, and they disappear after four to six weeks (Edinoff et al., 2022). To reduce the risk of serotonin syndrome, she is not expected to consume alcohol and non-prescription medicines containing dextromethorphan or St. John’s Wort.

Orthostatic dizziness may also occur, and this is why she should not rise suddenly after sitting. It is necessary to emphasize adherence even though the benefits might be realized in the long run in order to maximize the outcomes. We can jointly draw up a treatment plan by balancing the benefits of each medication on mood and functioning against the side-effect profile, and her history of health.

Describes Disease Pathophysiology Impact

Care Priorities

The most significant one is to make Ms. Jackson safe and stable. This includes regular screening of suicide risk and development of a safety plan with the collaboration (APA practice guidelines) (Horowitz et al., 2023). Second, optimizing the pharmacotherapy, including assessing the efficacy and tolerability of escitalopram, early side effects, such as gastrointestinal upset, insomnia, or hyponatremia, and increasing or switching the dose or considering augmentation at week 6 in case of a lack of improvement in mood (Parish et al., 2023).

Third, addressing sleep disturbance and energy deficits through adjunctive nonpharmacologic interventions (e.g., sleep hygiene, structured activity scheduling) as well as her meditation practice. Finally, to alleviate cognitive distortions and interpersonal stressors as a result of her divorce, it is possible to facilitate evidence-based psychotherapy (CBT or IPT) (Srivastava et al., 2024).

• Integration of Assessment, Pharmacology, and Pathophysiology

The slowing of the psychomotor activity, loss of weight, and insomnia experienced by Ms. Jackson are all symptoms of the monoamine dysregulation and hyperactivity of the HPA-axis that is symptomatic of major depression disorders. By assigning these effects to her past, hypertension on hydrochlorothiazide and lisinopril, and previous venlafaxine discontinuation, we had put a value on an SSRI that has a favourable cardiovascular and metabolic safety profile. The low P450 interaction of escitalopram decreases the chances of adverse drug-drug interactions and diuretic-induced hyponatremia (Chu & Wadhwa, 2025). Close monitoring of her symptom patterns and adverse effects is the best practice in SSRI management, given that improvement of symptoms through normalization of neurotransmitters may take up to four to six weeks.

• Evidence-Based Support

These priorities are also endorsed by the APA recommendations on MDD, in which the emphasis is placed on the early safety assessment and measurement-based care as a tool for managing treatment adjustments. The American College of Physicians suggested that SSRIs be considered the first-line drug in older adults due to their safety (Karrouri et al., 2021).

The suggestions of Bartova et al. (2021) supported the combination of pharmacotherapy and structured psychotherapy in order to reduce the likelihood of relapse and improve functional recovery. Our care plan is aligned with the best current practices since it combines the clinical profile of Ms. Jackson, her drug history and her neurobiological processes to maximize outcomes and future well-being.

Conclusion

Major depressive disorder is the condition of Ms. Jackson due to persistent sadness, anhedonia, weight loss, sleep disturbance, and psychomotor retardation as a result of the separation in marriage. Other causes are eradicated by the normal levels of thyroid and vitamin D. She has begun taking escitalopram and has already seen some improvement in sleep at an early stage, and meditates. Constant monitoring of the symptoms, medication effects, and the introduction of evidence-based psychotherapy will be encouraged to achieve such a gradual recovery.

Ace your NURS FPX 4015 Assessment 5 Comprehensive Head-to-Toe Assessment with expert help from Tutors Academy. Get step-by-step guidance and score top grades.